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Abstract
We previously investigated a sample of patients during an active phase of psychosis in the search for genetic predictors of
haloperidol induced side effects. In the present work we extend the genetic association analysis to a wider panel of genetic
variations, including 508 variations located in 96 genes. The original sample included 96 patients. An independent group of
357 patients from the CATIE study served as a replication sample. Outcomes in the investigation sample were the variation
through time of: 1) the ESRS and UKU total scores 2) ESRS and UKU subscales (neurologic and psychic were included) related
to tremors and 3) ESRS and UKU subscales that do not relate to tremors. Outcome in the replication sample was the
presence vs absence of motoric side effects from baseline to visit 1 (, one month of treatment) as assessed by the AIMS
scale test. Rs2242480 located in the CYP3A4 was associated with a different distribution of the UKU neurologic scores
through time (permutated p= 0.047) along with a trend for a different haloperidol plasma levels (lower in CC subjects). This
finding was not replicated in the CATIE sample. In conclusion, we did not find conclusive evidence for a major association
between the investigated variations and haloperidol induced motoric side effects
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Introduction
Schizophrenia is a chronic devastating illness with a world wide
prevalence of about one percent. Its treatment includes the use of
antipsychotics, a class of drugs that antagonize, among others, the
dopaminergic 2 receptors. Haloperidol is a benchmark drug for
the pharmacological treatment of Schizophrenia. The genetic
background of its effect and side effects remains to be clarified
even though sensitivity to antipsychotics’ induced side effects varies
in the general population, and genetics may play a role in creating
such differences [1]. In particular, knowing in advance who will
develop intolerable side effects would help avoid the premature
discontinuation of the pharmacological treatment which would
result in a better prognosis [2]. A list of genetic variations has been
associated with side effects caused by antipsychotics. A review can
be found at [3]. In particular, the dopaminergic 2 receptor seems
to play a major role [4]. Further, some recent genome-wide
investigations widened the number of molecular pathways and
candidate genes that could be of prime relevance in determining
movement disorders after treatment with antipsychotics. Alkelai
and colleagues [5] investigated a sample from ‘The Clinical
Antipsychotic Trial of Intervention Effectiveness’ (CATIE) (n
tot = 397 – in that analysis - , output was the score from the
Simpson-Angus Scale (SAS) for Parkinsonism [6]. Three genes
were associated with motoric side effects: EPF1, NOVA1 and
FIGN. EPF1 product is a transcription factor that controls
neurogenesis in the CNS [7], and it can be crucial in the
migration of dopaminergic neurons to the substantia nigra [8].
FIGN product is a chaperon, a protein involved in pro-surviving
events. The NOVA1 product is the neuro-oncological ventral
antigen 1. Aberg and colleagues [9] analyzed a larger sample from
the CATIE (n = 738 in that second analysis, output was the score
from the following tests: SAS for Parkinsonism, the Barnes
Akathisia Rating Scale (BARS) [10] and the abnormal involuntary
movement scale (AIMS)(www.servier.com/App_Download/
Neurosciences/…/AIMS.pdf) and brought convincing evidence
that a zink protein (ZNF202) plays a role in determining the risk
for motoric side effects induced by antipsychotics. This gene codes
for a transcription suppressor which is particularly active in lipidic
related genes. Aberg and colleagues argued that ZNF202 could
play a role in the synthesis of myelin.
Tardive dyskinesia has been extensively investigated by
pharmacogenetic studies as a severe and potentially irreversible
motoric side effect inducted by antipsychotics. A complete and
recent review can be found at [11]. Acute and potentially
reversible motoric side effects induced by antipyschotics received
much less attention, even though their incidence may dramatically
decrease adherence to treatment, which leads to a poorer
prognosis. Table 1 reports the main genetics findings published
insofar. One of the most frequently investigated gene was the
CYP2D6, a gene that encodes a member of the cytochrome P450
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e44853
superfamily of enzymes. The cytochrome P450 proteins are
monooxygenases which catalyze many reactions involved in drug
metabolism and synthesis of cholesterol, steroids and other lipids.
This protein localizes to the endoplasmic reticulum and is known
to metabolize as many as 20% of commonly prescribed drugs,
included many psychotropic drugs. The gene is highly polymor-
phic in the population; certain alleles result in the poor
metabolizer phenotype, characterized by a decreased ability to
metabolize the enzyme’s substrates. On this basis, a number of
pharmacogenetic investigations were conducted to find out
whether variations in this gene that resulted into different drug
plasma concentrations could interfere with the risk of developing
an acute motoric side effect after antipsychotic treatment. Despite
highly rational, this approach did not provide consistent evidence
of involvement of the CYP2D6 polymorphisms in the incidence of
motoric side effects incuded by antipsychotics (Table 1). The
reason for that may be found in both the biological complexity and
the caveats of the studies that dealt with this gene. There are many
other proteins that may balance a decreased function of the
CYP2D6, thus blunting the pharmacogenetic effect of this
variation. For example the human multidrug resistance gene
(MDR1) codes for a P-glycoprotein that acts as a an ATP-
dependent efflux transporter that protects the central nervous
system from environmental toxins and xenobioticsmay. Variations
located in the MDR1 may modulate the functionality of the coded
protein that may balance the hypo/hyper activity of the CYPD26.
Thus, studies that did not take into account the variations located
in the CYP2D6 and the MDR1 may suffer from a relevant
biological stratification factor. Consistently with this, two varia-
tions located in the gene that code for the MDR1 (Table 1) were
found to be associated with dystonia and akathisia in a sample of
56 Caucasian patients treated with risperidone [12]. Further, the
medium-small samples enrolled for the analyses of the CYPD2D6
variations (Table 1) decreased the power of the studies, so that
minor genetic effects passed undetected. The serotonin trasporter
(5-HTT) [13], and the dopamine transporter (DAT1) [14] were
also investigated as potential modulators of antipsychotic induced
side effects. Interestingly, Guzey and colleages reported that the
DAT1 VNTR polymorphism and the dopamine receptor D2
(DRD2) Taq1A A1 associated with the DAT1 VNTR 9 repeat
alleles were associated with higher risk of extrapyramidal side
effects in a sample of 119 Caucasian patients treated with different
antipsychotics. This finding is particularly interesting in that the
DAT1 regulates the dopamine turnover and the DRD2 is one of
the main molecular targets of antipychotics, the blockage thereof is
considered to be central to the development of motoric side effects
[11]. Consistently, the Ser9Gly variant of the dopaminergic
receptor D3 gene (DRD3) was also found to be involved as a risk
factor in the incidence of motoric side effects after antipsychotic
treatment [15]. Nevertheless, the role of mutations located in
dopaminergic receptors was not confirmed in a large sample of
665 patients [16]. Different study designs and medications could
be at the basis of this lack of replication. We could not find a
genetic association between the short/long promoter variation in
the serotonin trasnporter and antipsychotic induced motoric side
effects, but the study was exploratory with a small sample (47
subjects) to hold enough power to detect minor genetic effects [13].
The serotoninergic system was nevertheless proved to hold a
potential for being a mediator of motoric effects induced by
antipsyhotics. The serotonin receptors 2C and 2A were investi-
gated in the same study we conducted for analysing the impact of
the serotonin transporter variations. Despite the sample was small,
we could identify an impact of the 102C allele of HTR2A and the
2697C and 23Ser alleles of HTR2C which were more frequent
among patients with extrapyramidal side effects [13]. This finding
could not be replicated in a larger sample though [14], and more
research is needed to clarify the impact of the serotoninergic
system towards antipsychotic induced motor side effects. Antipsy-
chotic induced parkinsonism was associated with a multiallelic
variation in ATP1A3 gene in a study that involved 156 Caucasian
patients [17]. ATP1A3 codes for a P-type cation transport, an
ATPase integral membrane protein responsible for establishing
and maintaining the electrochemical gradients of Na and K ions
across the plasma membrane.
Overall, evidence gathered in so far is not consistent enough to
provide the basis for a genetic tool to predict who will develop side
effects when taking antipsychotic drug treatments [1]. Further
research is then required. In the present paper we focus on
motoric side effects caused by haloperidol in a sample of acutely ill
psychotic in patients previously investigated both from a clinical
[18,19] and a genetic [18] point of view. We also replicated our
findings on a public available genome-wide database from the
NIMH funded CATIE (Clinical Antipsychotic Trials in Interven-
tion Effectiveness) [20].
Materials and Methods
We used a sample for investigation (n tot = 101, n with complete
genetic data = 96, psychotic patients treated with haloperidol) and
a sample for replication (n tot = 357, psychotic patients from the
CATIE study).
Sample for investigation
Characteristics of the sample for investigation. This
sample has been described in detail elsewhere [19]. Briefly, 96 (42
females) acutely ill patients of Caucasian descendant were treated
with haloperidol and assessed for a period of one month. Patients
were enrolled at the Department of Psychiatry, Ludwig-Max-
imilian-University of Munich, Germany. Exclusion criteria were
not having signed the informed consent for the study, a known
contraindication for treatment with haloperidol, tardive dyskine-
sia, severe neurological or medical disorders, organic brain
diseases, pregnancy and acute suicidality. Furthermore, patients
were excluded if they received comedications, such as beta
blockers, antidepressants, or benzodiazepines with a possible
influence on the antipsychotic treatment and its side effect.
Patients were treated with haloperidol during the acute phase of
the illness and then shifted to another antipsychotic treatment in
case of lack of response or severe side effects. Diagnosis was
obtained through the SCID interview and psychopathological
measurements administered by two psychiatrists with reliable
inter-rater evaluation results (k.0.80). Haloperidol plasma levels,
the Udvalg for Kliniske Undersøgelser side effect rating scale
(UKU) [21] and Extrapyramidal Symptom Rating Scale (ESRS)
[22] scores were assessed more than weekly during the first month
of treatment. The study was approved by the ethics committee of
the Ludwig-Maximilian University and carried out in accordance
with the ethical standards laid down in the 1964 Declaration of
Helsinki and later revisions. A format for the written consent is
attached to the present application. For being included in the
study, patients had do give written consent to their participation.
All potential participants who declined to participate or otherwise
did not participate were eligible for treatment (if applicable) and
were not disadvantaged in any other way by not participating in
the study.
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Characteristics of the replication sample
The CATIE (Clinical Antipsychotic Trials for Intervention
Effectiveness) Schizophrenia Trial was a National Institute of
Mental Health (NIMH) funded large, double-blind trial that
compared the effectiveness of five antipsychotics in the treatment
of schizophrenia. These drugs included four atypical SGAs (second
generation antipsychotcis: olanzapine, quetiapine, risperidone,
and ziprasidone, all introduced since 1994) and perphenazine (a
medium-potency, conventional FGA (first generation antipsychot-
ics) available since the 1950s). Fourteen hundred sixty adults with
schizophrenia were studied for up to 18 months. Diagnoses were
determined by Structured Clinical Interview for DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders, fourth
edition). The study was a pragmatic hybrid of efficacy and
effectiveness trial designs [23]. Ages ranged from 18 to 65.
Inclusion criteria allowed patients with comorbid medical,
psychiatric, and substance abuse problems to participate in the
study, consistent with ‘‘real world’’ design. Patients were also
excluded if they had a diagnosis of schizoaffective disorder, mental
retardation, or other cognitive disorders, as were those who were
treatment resistant (defined as persisting severe symptoms despite
adequate trials of one of the study medications or prior treatment
with clozapine). Patients with severe or unstable medical
conditions and pregnant women were excluded. Study participants
provided written informed consent following discussion of the
study and formal testing to demonstrate understanding of its
elements [20]. The CATIE trial consisted of three phases. Data
from the phase 1 served for replication in the present article.
In Phase 1, participants were randomly assigned to double-blind
treatment of up to 18 months either with one of the four SGAs or
with perphenazine. Patients with TD (tardive dyskinesia) were not
administered perphenazine. The primary outcome measure of the
study was all-cause treatment discontinuation, but a number of
tests were administered to patients, including the AIMS which
served for replication in our sample. Phase 1 examined 1460
intent-to-treat subjects. Genome-wide data was available for
410schizophrenia patients as retrieved - upon request – from
https://www.nimhgenetics.org/available_data/schizophrenia/
pgc/pgc_sz1.php. . Inclusion criteria from the original CATIE
study were having been treated with a first generation antipsy-
chotic before entering the study and being not missing in the
outcome measures. The first inclusion criteria was set in order to
match the cases in the group for replication with the cases in the
original group. Subjects were then analyzed irrespectively of the
kind of antipsychotic they were administered. The rational for this
approach is that motoric side effects from a first generation
antipsychotic may appear weeks after its introduction. Thus, we
included all subjects treated with a first generation antipsychotic at
baseline and followed them for, a month. On the other hand, the
introduction of a second generation antipsychotic may decrease
the antipsychotic induced motoric side effects. Then the clinical
baseline scores were employed only when scores at visit 1 were
missing.
Outcome in the sample for investigation
Primary outcome in the sample for investigation was the
variation over time of the sum of ESRS [22] items related to
tremors (ESRS questionnaire item 7 = ‘Tremors, shaking’; ESRS
parkinsonism item 5: ‘tremor right arm’,’tremor left arm’, ‘tremor
right leg’,‘tremor left leg’,‘tremor head’,‘tremor jaws’,‘tremor
tongue’,‘tremor lips’), and the UKU [21] neurologic and
autonomic scores. Tremors are included in the UKU neurologic
subscales and were analyzed separately. Missing values were
handled by a last observation carried forward analysis.
Clinical covariates in the sample for investigation
Haloperidol plasma levels were the clinical covariate in the
sample under investigation, based on the results of a previous
analysis of the same sample [24]. Haloperidol plasma levels were
not included in the model as covariates when the genes
pharmacokinetically related to haloperidol were analyzed.
Outcome in the replication sample
Outcomes in the replication sample were dichotomic and
corresponded to a $1 score at the SEVSCORE (AIMS [22] sums
of scores from 1 to 7), BRSOBJ (Barnes akathisia scale [10], sum of
scores from 1 to 3) and EPSMEAN (Simpson-Angus Scale
Movement Score [6], mean of items 1 to 6) at visit 1. For
EPSMEAN a threshold for defining presence/absence of side
effects was the median of the distribution of the variable. When
any of these scores were missing, a score $1 at the Movement
Severity Score at baseline was used instead. All the variables were
available and no further edited from the original data.
Predictors
A list of 508 variations were analyzed as predictors of the
outcomes in the investigation sample. 508 variations located in
known candidate genes were selected for the analysis. Candidates
included genes involved in cell-to-cell and cell-to-matrix interac-
tion (ADAM22 for example), glutamatergic and GABAergic
related genes (GRIA4 and GABRA4 for example) and genes
related to the pharmacokinetics of antipsychotics (e.g. CYP2D6).
The most significant findings were investigated as predictors in
the CATIE sample in order to reduce the probability of false
positive findings. The CATIE sample was imputed to allow the
replication of the same variants in both samples. These genes
extended a panel of about one hundred variations that were
previously investigated in the same sample [18]. Supplementary
material reports the total of investigated variations in the present
analysis (Table S1).
Genotyping in the sample for investigation
Genotyping. SNPs were chosen in order to balance the
maximum gene coverage and the costs of the analysis. A medium
of 5 variations for each gene were included in the analysis.
DNA extraction was done with the QIAamp Blood Maxi Kit
(QIAamp DNA Blood Midi/Maxi Handbook, Firma Qiagen,
Hilden, Germany, 2005). DNA concentration was adjusted
using the PicoGreen quantitation reagent (Invitrogen, Karls-
ruhe, Germany). SNPs were selected from the NCBI
SNP database http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db = snp), pubmed publications (http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?db = PubMed) and ‘‘Tagger’’ (http://
www.broad.mit.edu/mpg/tagger/server.html). Only validated
SNPs with a minor allele frequency of more than 1% were
selected. All SNPs were in Hardy–Weinberg Equilibrium
(p,0.01). 12,5 ng DNA were genotyped using the iPLEX assay
on the MassARRAY MALDI-TOF mass spectrometer (SE-
QUENOM, Hamburg, Germany). Genotyping call rates in
cases and controls were all .96%. Allele frequencies were
similar to CEU sample frequencies (www.hapmap.org).
The list of genes and SNPs investigated is reported in
Supplementary materials.
Genotyping in the replication sample
We employed the public available NIMH CATIE dataset.
Individual genotypes were downloaded from the net. As for the the
methods in the original study, individual genotyping was
CYP3A4 and Haloperidol Side Effects
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conducted by Perlegen Sciences (Mountain View, CA, USA) using
three genotyping chips: Affymetrix 500 K ‘A’ chipset (Nsp I and
Sty I chips; Santa Clara, CA, USA) and a custom 164 K chip
created by Perlegen [25] to provide additional genome coverage,
further details can be found at [26].
Data imputation in the replication sample
Imputation procedure was conducted in PLINK (Purcell et al.
2007), source for imputation was the hapmap_CEU_r23a dataset
(http://pngu.mgh.harvard.edu/,purcell/plink/res.shtml.). To
speed up the procedures, only the parts of the genome harboring
the variations found to be associated with outcome in the
investigation sample were imputed. A quality threshold for
imputation of 0.95 was required.
Statistics
Repeated measures ANOVA was the test of choice to study the
association between genotypes and primary outcome in the sample
of primary investigation. The analysis of clinical covariates was
conducted in previous publications [27]. Haloperidol plasma levels
were not included as covariates when genes related to the
pharmacokinetics of haloperidol were analyzed as predictors, in
that the haloperidol plasma levels would be an effect rather than a
confounder of such genes’ activity. Time was included as a
continuous variable and the gene*time effect was investigated. A
logistic regression between the outcome (presence/absence of
motoric side effects) and the predictors (best SNPs from the
primary analysis) was the test of choice in the replication sample.
All non genome-wide analyses were run in R [28], dedicated
packages. For the analyses that implicated the investigation of part
of the genome-wide data we employed Plink [29]. We had
sufficient power (0.80) to detect a medium effect size (,0.5)
between three groups (three genotypes) each composed by 33
subjects on average.
Results
Sample characteristics of the investigation sample are reported
in table 2. Table 3 reports the distribution of the outcome in the
primary sample. Table 4 reports the significant different distribu-
tion of the outcome in the primary sample according to the
rs2242480 genetic variability. Table 5 reports the characteristics of
the sample for replication.
Rs2242480 located in CYP3A4 influenced the distribution of
the UKU neurological scores through time in the sample for
primary analysis (table 4). Moreover, it had an appreciable though
not significant effect on haloperidol plasma levels. There were 77
homozygotes for the C allele at rs2242480, 21 heterozygotes and 1
homozygote for the T allele. 8 subjects were missing. Analyses
were conducted again including the CC and CT genotypes only.
The final association with the distribution of UKU neurological
scores resulted robust (p = 5e-4; F = 7.68; df = 2) to survive 100000
permutations (permutated p = 0.047) (table 4) but not a Bonferroni
correction (p = 9.8e-5). No other association survived the permu-
tation, either from the principal or the secondary outcome. This
finding was not replicated in the CATIE sample. The lack of
replication mandate cautiousness in interpreting this result. No
haplotype analyses was then conducted based on the finding
involving the rs2242480 to avoid multitesting and possible false
positive findings. Supplementary material contains the character-
istics and gentotypic distribution of the variations under analysis.
Discussion and Conclusions
CYP3A4 is involved in the pharmacokinetics of haloperidol [30]
and its activity is induced by this drug [31]. Of note, CYP3A4 is
expressed also by the the blood brain barrier (BBB) and by
neurons [32]. A prosurviving activity of this enzyme in neuron was
consistently recently demonstrated [32].
Rs2242480 located in CYP3A4 was found to interfere with the
UKU neurological scores in a way which was not completely
accounted by the haloperidol plasma levels in the sample.
Intriguingly then, rs2242480 harbored by CYP3A4 could
dampen the ability of the BBB to stop haloperidol before it enters
the neuronal milieu or also the ability of neurons to handle the
toxic products of haloperidol metabolism [33]. Carriers of the CC
genotype would have either a lower neuro/blood haloperidol level
ratio, or their neurons would be more active in metabolizing the
neurotoxic products of haloperidol. The first hypothesis could be
objected because there was no effect of this variation in the
distribution of PANSS scores in the sample. Nevertheless, this
finding did not survive a Bonferroni correction as was not
replicated in the CATIE sample. Thus, the probability of a false
positive finding despite the biological rationale of this finding is
very high.
A long list of genes and variations were included in this analysis.
The present panel of investigation contained both genes that have
been investigated in candidate associations (dopamine 2 receptor
for example) and genes that belong to molecular pathways whose
activity is consistent with the results from the genome-wide
investigations. For example, we included a list of variations
harbored by ADAM22 whose product is involved in cell-cell and
cell-matrix interactions, and some transcription factors such as
PRDM2. The rational for such inclusion is consistent with the
proliferation and migration of neurons to the substantia nigra,
which has been suggested to be a pivotal molecular event for
antipsychotic induced movement disorders [5].
Nevertheless, no other significant association beside the
CYP3A4 was found in this analysis. This could be dependent on
the small sample size which prevented the identification of small
genetic effects towards the investigated phenotypes, or on the
incomplete gene coverage. On the other hand, the analysis of
Table 2. Sample clinical characteristics.
Variable Result Association with the outcome (p value)
Sex M=50; F = 46
TOT = 96
0.65
Age (yrs) (mean6SD) 34.23611.55 0.12
Age at onset (yrs) (mean6SD) 28.4369.58 0.07
Ethnicity Caucasian = 96 /
doi:10.1371/journal.pone.0044853.t002
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relevant variables such as the haloperidol plasma levels are more
feasible in smaller samples. This may be relevant in the search of a
better balance between the required sample size and the required
detail of clinical variables to detect the effects of the genetic
variations. Finally, some relevant genetic variants such as the copy
number variations or the epigenetic control were not investigated.
In conclusion, we found a variation harbored by the CYP3A4
gene with a trend of significant association with the UKU
neurologic scores distributionEven though rs2242480 was associ-
ated with a different distribution of haloperidol plasma levels in the
sample (table 4), this finding was not statistically significant. Thus,
the effects of this variation may be related also to a different ability
of neurons to handle higher levels of haloperidol. Then, it is
possible to hypothesize that the rs2242480 located in CYP3A4
may impact on the resilience of neurons to haloperidol toxicity but
further research is needed. Rs2242480 is located in the intron
region of NM_001202855.2 but it is very closed to an exonic
region (,20 b (http://www.ncbi.nlm.nih.gov/projects/SNP/
snp_ref.cgi?rs = 2242480)). Thus, it could play a role in impacting
the expression rate of the CYP3A4 by influencing the molecular
process at the boundary between the exonic and intronic region.
Consistently, this variation proved to be significantly associated
with adverse reactions to metadone [34] and with coronary disease
[35]. The lack of replication in the CATIE sample may be
attributable to the imputation analysis which could have
potentially affected the replication results and also to the clinical
Table 3. ESRS and UKU scores distribution through time in the discovery sample.
ESRS
ESRS total ESRS parkinsonism ESRS dystonia ESRS dyskinesia ESRS questionnaire
Day 1 0.0660.64 0.0160.1 0.0160.18 0.6261.41 0.0260.21
Day 03 15.20617.75 5.1167.28 3.5666.37 2.3063.71 4.2264.69
Day 07 14.37618.54 7.60610.29 1.3764 2.2063.24 3.7764.37
Day 14 15.10617.03 8.90611.36 0.5462.2 2.3762.51 3.8163.80
Day 21 15.24616.47 8.5869.67 0.0360.26 2.2362 3.2162.96
Day 28 14.40615.90 7.7668.29 / / 3.3362.89
UKU
UKU total UKU neurological UKU psychic
Day 1 7.7864.46 0.2060.89 7.2664.31
Day 03 8.5065.79 2.8963.23 5.6064.29
Day 07 7.4465.84 2.9763.38 4.4163.92
Day 14 7.2065.59 3.2663.26 3.9363.72
Day 21 6.4764.58 2.9762.53 3.5463.26
Day 28 5.964.01 2.8662.51 3.0362.49
Haloperidol plasma levels (microg/L)
Day 1 3.5164.42
Day 03 6.6567.24
Day 07 7.6969.82
Day 14 6.6164.54
Day 21 7.1065.74
Day 28 7.1566.11
doi:10.1371/journal.pone.0044853.t003
Table 4. UKU neurological scores haloperidol oral doses and plasma levels for CYP3A4 rs2242480.
UKU neurological scores Haloperidol oral doses Haloperidol plasma levels
rs2242480 CT CC CT CC CT CC
Day 1 0.12560.5 060 / / 1.9561.34 4.0964.97
Day 03 3.5662.44 2.4162.94 / / 7.2266.48 6.9167.77
Day 07 4.3763.70 2.1762.56 12.4666.44 10.4665.06 8.8865.53 7.71611.12
Day 14 4.6863.45 2.4162.40 10.9766.74 10.3565.98 9.4766.47 6.1363.82
Day 21 4.8163.37 2.2862.12 10.2368.09 10.6866.05 11.8867.73 6.5764.83
Day 28 4.7563.35 2.2062.06 10.3867.86 10.2567.25 12.50611.75 6.2863.70
/ = not detected.
doi:10.1371/journal.pone.0044853.t004
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characteristics of the sample which are not fully consistent with the
investigation sample. Moreover, the CATIE design aimed at
addressing compliance to the treatment more than addressing the
treatment efficacy, so that the comparison between the sample for
investigation and the sample for replication we used may have
suffered from relevant formal caveats.
Supporting Information
Table S1 Table S1 reports the complete list of investi-
gated variations.
(DOC)
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